Latest Conference Articles

Loomba reviews safety and efficacy data for the thyroid hormone receptor beta agonist from a phase 2a trial presented at AASLD The Liver Meeting 2024.

Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.

Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Marianna Fontana, MD, PhD discusses Phase 1 interim results on the CRISPR-based gene-editing therapy, nex-z, for ATTR-CM.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

At NASPGHAN, HCPLive spoke to Hamant about her team’s study that showed their algorithm was linked to increased VTE Prophylaxis among Pediatric IBD.

Barritt reviews real-world data about the use and benefits of GLP-1 RAs in patients with MASLD.

Bifidobacterium longum 35624TM reduces IBS symptom severity in children and adolescents, according to a study presented at NASPGHAN 2024.

At NASPGHAN 2024, HCPLive spoke with Duncan about how treating infants who appear to have reflux may actually result in greater repeat hospital visits.

Findings from the open-label extension of the ELATIVE study suggest sustained safety and efficacy for up to 3 years, with improvements in itch and sleep.

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Diabetes was associated with an increased risk of liver transplant or death and with liver-specific events in patients with PBC.

Marianna Fontana, MD, PhD describes the prognostic importance of a decline in eGFR in a retrospective cohort of patients with ATTR-CM.

Zhang explains the safety of different FDA-approved alcohol use disorder drugs in patients with alcohol-associated liver disease.

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

Liver transplant waitlisting after a weekend was associated with higher 1-year post-transplant mortality compared with patients listed on a weekday.

Teckman explains the value of a new predictive algorithm model for determining future risk of portal hypertension, cirrhosis, and liver transplant in AATD.

A nasal spray form of bumetanide reduced tissue swelling from heart failure as effectively as the oral and intravenous formulations.

Sacubitril/valsartan reduced the risk of heart damage among high-risk cancer patients treated with anthracycline chemotherapy agents.

GLP-1RA use was associated with a reduced risk of adverse liver outcomes in patients with alcohol-associated liver disease and type 2 diabetes.

Compared with non-Hispanic White patients, racial/ethnic minority patients were more likely to be removed from the waitlist and not receive a transplant.

Christian. T. Ruff, MD, MPH describes an analysis of AZALEA-TIMI 71 demonstrating the substantial benefit of abelacimab on bleeding outcomes in patients on antiplatelet therapy.

High adherence to the Mediterranean diet was linked to a lower risk of liver-related outcomes as measured by the Liver Risk score.

Ankeet Bhatt, MD, MBA, ScM, provides additional insight into NUDGE-FLU data he presented at AHA 2024.

Electronic messages highlighting cardiovascular benefits of flu shots increased vaccination rates by 1.8% in heart attack survivors.